Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience

• Published in: International journal of clinical oncology 2021-12, Vol.26 (12), p.2275-2281
• Main Authors: Uchihara, Masaki, Tanioka, Maki, Kojima, Yuki, Nishikawa, Tadaaki, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Maeshima, Akiko Miyagi, Yonemori, Kan
• Format: Article
• Language: English
• Subjects: Adolescent; Adrenal Cortex Neoplasms - drug therapy; Adrenocortical Carcinoma - drug therapy; Adult; Adverse events; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Cancer Research; Chemotherapy; Cisplatin; Cisplatin - adverse effects; Doxorubicin; Doxorubicin - adverse effects; Etoposide; Etoposide - adverse effects; Humans; Medicine; Medicine & Public Health; Metastases; Metastasis; Middle Aged; Mitotane - adverse effects; Neuroendocrine tumors; Oncology; Original Article; Patients; Retrospective Studies; Surgical Oncology; Survival; Treatment Outcome; Young Adult
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-021-02021-8

Background Adrenocortical carcinoma (ACC) is a rare and aggressive disease that is often diagnosed at an advanced stage. There is no standard treatment for metastatic ACC; EDP-M (etoposide, doxorubicin, and cisplatin plus mitotane) is one treatment option. A randomized controlled trial (FIRM-ACT) evaluating the efficacy of EDP-M showed progression-free survival (PFS) was 5.0 months, overall survival (OS) was 14.8 months, the response rate was 19%, and adrenal insufficiency occurred in 3.4% of patients. However, the efficacy and safety of this regimen in Asia are not fully reported. Methods We retrospectively analyzed 43 patients diagnosed with metastatic ACC at the National Cancer Center Hospital between 1997 and 2020. We evaluated PFS, OS, and response in 17 patients who received EDP-M as first-line therapy. Results The median age at treatment initiation was 45 years (range 18–74). Eight patients (47%) had autonomous hormone production, including six patients with hypercortisolism. The best response of partial response and stable disease was seen in two (12%) and ten (59%) patients, respectively. The median PFS was 6.2 months [95% confidence interval (CI): 4.3–10.0]. The median OS was 15.4 months (95% CI 11.6–not reached). Three patients received only one cycle due to adverse effects associated with hypercortisolism. Grade 3/4 adverse events associated with adrenal insufficiency occurred in three (17%) cases, resulting in EDP-M discontinuation. Conclusions The EDP-M regimen had similar PFS to that observed in FIRM-ACT. Adrenal insufficiency was more frequent in the current study, but this could be managed with supportive endocrinological care such as cortisol replacement.